Market Update
February 02 2009 - 11:22AM
UK Regulatory
TIDMYRK
RNS Number : 6588M
York Pharma plc
02 February 2009
York Pharma plc
("York" or the "Company")
Market Update
Milton Keynes, UK, 2 February 2009, York Pharma plc (YRK.L), the specialist
dermatology company, provides the following update to its strategic review
announced on 14 January 2009.
The recently strengthened management team has now assessed the current position
of the Company and initiated steps to simplify and focus the existing business.
As a consequence the Board has agreed the following actions:
* The closure of York's existing representative office in Japan with immediate
effect;
* A significant reduction of the Company's existing infrastructure in Germany;
* A review of the development pipeline to identify assets within the portfolio to
be divested; and
* To continue the development of the late stage dermatology pipeline whilst
minimising the investment required by the Company
The strategic review is ongoing and the Company is continuing to assess resource
levels within the business to ensure that they are appropriate whilst taking all
possible steps to maintain an adequate level of working capital. The Company is
also investigating a number of options to address its short term funding
requirements. The Company will continue to update the market as further progress
is made.
Richard Anderson, York's Chief Executive, commented:
"The new management team has moved swiftly to cut costs and to refocus the core
business. We are also moving ahead with the next phase of our plan which is to
build on the stable platform being created as a result of the restructuring so
as to establish a cash generative business. I believe that York remains an
attractive, revenue generating speciality pharmaceutical business with a strong
late stage pipeline."
For more information please contact:
+-----------------------------------------+------------------------------+
| York Pharma plc | Tel: +44 (0) 870 066 4453 |
| Richard Anderson, Chief Executive | |
| Officer | |
+-----------------------------------------+------------------------------+
| Collins Stewart Europe Limited | Tel: +44 (0) 207 523 8350 |
| Hugh Field / Adam Cowen | |
+-----------------------------------------+------------------------------+
| FinnCap | Tel: +44 (0) 207 600 1658 |
| Geoff Nash | |
+-----------------------------------------+------------------------------+
| Financial Dynamics | Tel: +44 (0) 207 831 3113 |
| David Yates / Ben Brewerton / Emma | |
| Thompson | |
+-----------------------------------------+------------------------------+
About York Pharma PLC
YORK PHARMA PLC is a pharmaceutical Group, established in 2003, which develops,
markets and supplies branded dermatological products to pharmaceutical
wholesalers, hospitals and general practitioners within the field of
dermatology.
The Group currently has at its disposal more than 20 patent families (with over
100 individual patents/patent applications) and intellectual property in
relation to its portfolio of novel dermatology products and technology platforms
in the key therapeutic areas of fungal infection, eczema/dermatitis, psoriasis,
vitiligo and acne that make up more than 87% of the global $10bn dermatology
market. For more information, visit www.yorkpharma.com.
- end -
This information is provided by RNS
The company news service from the London Stock Exchange
END
TSTUUUBGPUPBGQP
York Pharma (LSE:YRK)
Historical Stock Chart
From Jun 2024 to Jul 2024
York Pharma (LSE:YRK)
Historical Stock Chart
From Jul 2023 to Jul 2024